key: cord-0998241-wg641kli authors: Pagani, G.; Bernacchia, D.; Conti, F.; Giacomelli, A.; Rondanin, R.; Scolari, V.; Boracchi, P.; Gandolfi, C. E.; Castaldi, S.; Biganzoli, E. M.; Galli, M. title: Dynamics of the SARS-CoV-2 epidemic in the earliest-affected areas in Italy: 1 Mass screening for SARS-CoV-2 serological positivity (SARS-2-SCREEN). date: 2020-06-08 journal: nan DOI: 10.1101/2020.06.06.20124081 sha: b3a459935f12bf9135e4984c10f20885daa9a245 doc_id: 998241 cord_uid: wg641kli Background Several municipalities in the Lombardy Region have been affected by the SARS-CoV-2 infection since the earliest stages of the epidemic. To date, 89442 confirmed cases have been diagnosed in Lombardy, and mortality in several municipalities has already surpassed that of the past decade. Currently, the true extent of the SARS-CoV-2 infection remains unknown as several affected subjects may have been asymptomatic or have presented mild disease, thus not resulting in the identified COVID-19 cases. Methods This cross-sectional study aims to define the spread of infection within the population by determining the seroprevalence of IgG antibodies directed against SARS-CoV-2 by rapid immunochromatographic testing and subsequent confirmation by serology on venous blood by liquid phase immunochemical testing, also allowing to compare the two methods. Testing will be performed on adults and minors residing, domiciled or working in several municipalities of the Lombardy Region, involved in the initial stages of the epidemic. The study will include rapid finger-prick testing and venous sampling for antibodies against SARS-CoV-2, and nasopharyngeal swabbing (NPS). Concurrent notification of test results will occur via the regional healthcare information system (SISS). Discussion This study was developed with the desire to understand the seroprevalence of SARS-CoV-2 infection and the epidemiological transmission characteristics of this virus. Understanding the spread and severity of the disease could help in the implementation of effective infection surveillance containment and countermeasures facilitating the identification of cases that have been exposed to the virus and the traceability of contacts. This study has been approved by the Ethics Committee of the University of Milan (35/2020). rapid finger-prick testing and venous sampling for antibodies against SARS-CoV-2, and 48 nasopharyngeal swabbing (NPS). Concurrent notification of test results will occur via the 49 regional healthcare information system (SISS). 50 Discussion This study was developed with the desire to understand the seroprevalence of 51 Understanding the spread and severity of the disease could help in the implementation of 53 effective infection surveillance containment and countermeasures facilitating the identification 54 of cases that have been exposed to the virus and the traceability of contacts. 55 (35/2020). 57 58 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 8, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 8, 2020. To date, the only diagnostic tool to be officially recognized by the Italian Ministry of Health 107 for SARS-CoV-2 infection is the NPS, that uses real-time reverse transcription polymerase 108 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 8, 2020. . https://doi.org/10.1101/2020.06.06.20124081 doi: medRxiv preprint 5 chain reaction (rRT-PCR) to identify and amplify traces of the SARS-CoV-2 genome within a 109 patient's sample5. This diagnostic method has several limits, including high costs, long 110 complete analysis times, and many false negatives (low diagnostic sensitivity). 111 Alongside the diagnostic aspect, the development of knowledge regarding disease spread and 112 prevalence in the population will become increasingly important in the near future. facilitating the identification of cases that have been exposed to the virus and the traceability of 120 contacts. 121 The primary objective of this cross-sectional study is to determine the spread of infection within 124 the population by determining the seroprevalence of IgG antibodies directed against SARS-125 CoV-2 by rapid immunochromatographic testing and subsequent confirmation by serology on 126 venous blood by liquid phase immunochemical testing. 127 Secondary objectives include comparing IgG and IgM antibody positivity obtained by rapid 128 testing via direct viral research to serological data obtained by the immunochemical method. 129 We also aim to establish a database for future prospective projects eg. serial antibody titer 130 assessed over time, possibly expanding the study to several municipalities particularly affected 131 by the SARS-CoV-2 epidemic around the Lombardy region. This may help localize and isolate 132 possible current and future outbreaks. 133 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 8, 2020. . https://doi.org/10.1101/2020.06.06.20124081 doi: medRxiv preprint 6 For the municipalities included in first so-called "red zone", thus more severely hit, we 134 hypothesize a seroprevalence of IgG antibodies directed against SARS-CoV-2 between 30% 135 and 50%, due to probable unrestricted viral circulation in the days or weeks before the first 136 hospitalized case. For the other, less severely affected, municipalities we estimate a prevalence 137 between 10 and 30%. 138 According to current regional legislation (DGR n. XI/3114 and DGR n. XI/3131) during the 139 second phase of the epidemic, NPS will be performed in all symptomatic individuals, flagged 140 as "suspect COVID-19 cases" by their family doctor, and in all traced contacts prior to 141 readmission in society. Although rRT-PCR on NPS is the current gold standard diagnostic test 142 for SARS-CoV-2, diagnostic accuracy depends on several pre-analytical and analytical 143 variables, and many patients can be asymptomatic (thus currently will not receive testing in the 144 Lombardy region). The measurement of specific COVID-19 antibodies could serve as an 145 additional tool for disease detection and management, playing a potential key role in 146 surveillance and screening. The latter may be even more advantageous if implemented in the 147 form of rapid finger-prick testing. In fact, as mentioned above, one of our secondary objectives 148 is the comparison of IgG and IgM antibody positivity obtained by rapid testing, to serological 149 data obtained by the immunochemical method. We hypothesize that antibody detection by rapid 150 finger-prick testing will be non-inferior to detection by venous sampling. 151 Testing will be performed at specific locations in the various municipalities, equipped with the 152 following rooms: 153 • A waiting room of suitable size to allow the simultaneous presence of 8-10 evenly 154 spaced (at least 1.8 m apart) individuals equipped with suitable PPE (surgical masks). 155 • A room for collection of personal data and for carrying out rapid tests. 156 • A room for the execution of venous blood samples. 157 • A room for carrying out NPS. 158 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 8, 2020. suggestive for acute infection will be evaluated by medical personnel to determine the 179 need for further investigations (imaging or ER access) and quarantined, at home or in a 180 different location if home is deemed unsuitable, pending swab results. These individuals 181 will receive extensive counseling on best-practices during the quarantine period. 182 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 8, 2020. . https://doi.org/10.1101/2020.06.06.20124081 doi: medRxiv preprint 8 3. Individuals with positive results to IgM rapid testing, regardless of IgG results, will be 183 quarantined at home, or in a different location if home is deemed unsuitable, pending 184 swab results. If swab results are also positive, quarantine will be confirmed and 185 extended and counseling on best-practices during the quarantine period will be 186 provided. 187 4. Individuals with positive results to IgG rapid testing only will be sent home, without 188 need for fiduciary quarantine. 189 5. Quarantined individuals will be provided with pulse oximeter, surgical masks and 190 extensive counseling on best-practices during the quarantine period. 191 6. All swab positive individuals, regardless of rapid test results, will be notified to local 192 health authorities using a specific infectious disease digital notification platform for the 193 Lombardy Region. The swab positive individual will thus be quarantined, and follow-194 up will be carried out by the local health authorities, as indicated in current regional 195 protocols. 196 197 Rapid test results will be communicated in real time and a full report comprising collected 199 anamnestic and epidemiological data, and rapid test results will be emailed or printed, according 200 to patient preference. 201 NPS results will be communicated as follows: 202 -In case of a negative result, attending medical personnel will call the patient directly. 203 -In case of a positive result, attending medical personnel will call the patient's family 204 doctor, who will then notify the local health authorities via the regional infectious 205 disease digital notification platform, and communicate the positive result to the patient. 206 207 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 8, 2020. . https://doi.org/10.1101/2020.06.06.20124081 doi: medRxiv preprint Sample management 208 1. Rapid tests will be analyzed by assigned staff within the timeframe suggested by the 209 manufacturer and will then be suitably disposed of by the same staff (biohazardous 210 waste). 211 2. Venous blood samples will be stored on site, refrigerated at +4°C, and transported to 212 the lab for analysis, daily. 213 3. Swabs will be stored on site, refrigerated at +4°C, and transported to the lab for analysis, 214 daily (or within 48 hours during the weekend). NPSs are placed in a triple container 215 during transportation: the collection tube is placed in a conical tube ("falcon" type tube), 216 and then in a spill proof box. 217 218 For the purposes of the primary objective of the study, random sampling will be carried out 220 from the municipal registry list, stratifying by gender and conventional age classes (0-19; 20-221 39; 40-59; >=60). At present, geographical stratification does not seem necessary given the 222 homogenous distribution of cases identified to date. Confirmed cases that have already been 223 identified in the municipality must be included in the study sample with the same probability 224 as other subjects. In fact, the rapid test and venous sample seroprevalence results on previously 225 confirmed cases will provide further data useful for comparison. 226 A sample size of 355 subjects from a population of 4616 individuals provides a bilateral 95% 227 confidence interval with an accuracy (half-amplitude) of 0.05 when actual prevalence is close 228 to 0.56. In case of higher or lower prevalence, the sample size decreases to 302 subjects in case 229 of prevalence equaling 0.3, very close to current estimates, and to 234 subjects in case of a more 230 skeptical prevalence hypothesis of 0.8. Considering the largest population sample combined to 231 a possible 20% drop-out, sample size increases to 444 subjects. 232 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Regarding the secondary objective, relating to sensitivity and specificity of the rapid test 236 compared to the gold-standard on venous blood samples, the sample size required for a bilateral 237 95% confidence interval with a maximum amplitude of 0.1, is 527 subjects for sensitivity and 238 438 subjects for specificity, assuming a prevalence of 0.3 with optimal sensitivity and 239 specificity equal to 0.9. Thus, in order for both confidence intervals to have a maximum 240 amplitude of 0.1, the largest of the two sample sizes (527 subjects) must be chosen9. Also, 241 sample size should be further increased to 659 subjects to allow for 20% drop-out. 242 Accordingly, in case of hypothesized sensitivity and specificity values equal to 0.8, the sample 243 size should be increased to 880 subjects, and to 1100 subjects to include 20% drop-out. 244 However, in an optimal situation, the sample size required for the secondary objective appears 245 compatible with that needed for the primary objective. In fact, a study that could effectively 246 recruit at least 500 people would continue to offer expected amplitudes of confidence intervals 247 up to 0.144 for sensitivity and <0.1 for specificity, even in conditions of lower diagnostic 248 performance, always hypothesizing a prevalence of 0.3. 249 Sample size calculations were carried out using PASS v. 16.0.3 validated software. 250 Location and testing procedures 253 Testing will be performed at various locations in the selected municipalities, equipped with the 254 following rooms: 255 • A waiting room of suitable size to allow the simultaneous presence of 8-10 evenly 256 spaced (at least 1.8 m apart) individuals equipped with suitable PPE (surgical masks). 257 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 8, 2020. . https://doi.org/10.1101/2020.06.06.20124081 doi: medRxiv preprint • A room for collection of personal data and performing rapid tests. 258 • A room for the execution of venous blood samples. 259 • A room for carrying out NPS. 260 • A room for the dressing and undressing of healthcare workers. 261 • A storage room with refrigerator. 262 Separate paths will be defined for the entrance and exit of tested subjects, particularly to prevent 263 loitering between individuals waiting to be tested and those already tested, as well as to prevent 264 large gatherings in confined spaces like corridors, making social distancing impracticable. subjects, yet to be determined, chosen at random. 281 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 8, 2020. . https://doi.org/10.1101/2020.06.06.20124081 doi: medRxiv preprint Given that examining the largest number of people in the shortest time possible is of paramount 282 importance in a cross-sectional study, we decided to perform rapid testing as the first procedure, 283 and to gather epidemiological and anamnestic data while waiting for the appropriate reading 284 time (10 to 20 minutes). This will enable us to perform between 200 and 250 rapid tests per 285 day. 286 287 Seeing as the SARS-CoV-2 epidemic is still active in the Lombardy region, participant and 289 personnel safety will be a main concern. Personal protective equipment (PPE) and sanitization 290 of all rooms and equipment will be guaranteed for the all duration of the study. 291 All patients must be equipped with a correctly worn surgical mask and disposable gloves. 292 PPE will be provided according to personnel role, as follows: 293 1. Surgical mask and disposable gown for personnel assigned to anamnestic, personal data, 294 and rapid test collection 295 2. FFP2 or equivalent filtered mask, surgical cap, visor, gloves and waterproof disposable 296 gown for personnel assigned to NPS collection and venous sample collection. 297 Moreover, we decided to position a plexiglass barrier with a specifically-designed hole through 298 which the rapid test is performed. This guarantees additional safety for personnel assigned to 299 rapid testing and data collection, without the discomfort of wearing PPEs. The same barrier was 300 proposed to the nurses assigned to venous blood sampling, but was not implemented based on 301 previous negative experiences with this method of blood collection through the plexiglass 302 barrier. 303 Rooms and surfaces will be sanitized three times a day using 0.1-0.5% sodium hypochlorite 304 solution for large surfaces eg. floors, walls, chairs; and 62-71% alcohol for small surfaces 305 (whenever there is biological contamination) and remaining instrumentation. 306 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 8, 2020. . https://doi.org/10.1101/2020.06.06.20124081 doi: medRxiv preprint 13 Sanitization will be carried out with disposable cloths or paper towels, to be suitably eliminated 307 (biohazardous waste). 308 Sanitization of any medical devices (sphygmomanometer, pulse oximeter, etc.) will be carried 309 out between each use. 310 311 Study data will initially be stored on a certified database of the i-Care platform, provided by 313 MEDISPA. Subsequently, an original database will be created, in collaboration with the 314 University of Milan Data Science Research Center, for data processing and analysis, according 315 to i-Care database data protection requirements, from which data transfer will take place. 316 Patient data will be traceable to a completely anonymous identification code (no data from 317 which patient identity could be derived will be recorded), thus only the doctor assigned to 318 patient data collection and, if required, subjects authorized by national privacy regulations will 319 be able to trace data back to the specific patient via the abovementioned identification code. In 320 any case, these subjects are bound by confidentiality according to current legislation. Patient 321 data will be made public only via scientific publications or conferences, and only in anonymous 322 aggregate form, always respecting current privacy laws (including but not limited to, "legge 323 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 8, 2020. . https://doi.org/10.1101/2020.06.06.20124081 doi: medRxiv preprint Total COVID-19 cases by province. In: COVID-19 in Italy -Monitoring by the Civil 359 Protection Department Epidemiological and clinical 363 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a 364 descriptive study Director-General's opening remarks at the media briefing on COVID-2019) R&D. WHO. World Health Organization Accessed 27 COVID-19 Report by ISS n. 11/2020 -Reccomendations for the correct sampling, 372 conservation and analysis of COVID-19 oro/nasopharyngeal swabs Sample Size Tables for Clinical 375 Statistical Methods for Rates and Proportions Two-Sided Confidence Intervals for the Single Proportion: 379 Comparison of Seven Methods (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 8, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 8, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 8, 2020. The authors would like to acknowledge the substantial contribution provided by Medispa 443 s.r.l., which contributed to the protocol by providing expertise, personnel and the informatic 444 platform. 445 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 8, 2020. . https://doi.org/10.1101/2020.06.06.20124081 doi: medRxiv preprint